StonvexLoading…
StonvexStonvexStonvexCore line items from RGEN's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $194.25M | $738.26M | $540.34M | $351.54M |
Operating Income | $15.94M | $55.17M | $37.30M | $20.47M |
Net Income | $8.33M | $48.89M | $35.61M | $20.70M |
EPS (Diluted) | $0.15 | $0.86 | $0.63 | $0.37 |
Total Assets | $2.93B | $2.95B | $2.92B | $2.90B |
Total Liabilities | $825.31M | $843.57M | $840.62M | $839.89M |
Cash & Equivalents | $582.65M | $566.02M | $748.75M | $708.86M |
Free Cash Flow OCF − CapEx | $23.59M | $93.90M | $76.35M | $32.95M |
Shares Outstanding | 56.40M | 56.33M | 56.28M | 56.25M |